GSK welcomes key agreement to support global preparedness against pandemic influenza
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global preparedness for a future influenza pandemic.
Roche Group's first-quarter 2011 sales on track for full-year targets
- Details
- Category: Roche
In the first three months of 2011 Group sales remained stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs.
Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550)
- Details
- Category: Pfizer
Pfizer Inc. announced top-line results from the ORAL Scan Phase 3 study (A3921044) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.
Bayer's Rivaroxaban Submitted for Approval in Japan
- Details
- Category: Bayer
Bayer's rivaroxaban (Xarelto®) has been submitted for marketing approval in the prevention of stroke in patients with atrial fibrillation to the Japanese Ministry of Health, Labor and Welfare (MHLW).
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
- Details
- Category: Genzyme
Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease
Forest Laboratories Completes Acquisition of Clinical Data, Inc.
- Details
- Category: Business
Forest Laboratories, Inc. (NYSE: FRX) ("Forest") has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) ("Clinical Data") by means of what is known as a short-form merger under Delaware law.
Nycomed acquires distribution rights to product portfolio in Turkey
- Details
- Category: Nycomed
Nycomed has entered into several agreements with various pharmaceutical companies, including Almirall S.A., Anika Therapeutics, Inc., Bionorica AG, CSL Behring and Helsinn Healthcare SA.
More Pharma News ...
- Novartis discontinues clinical trial of Tasigna®
- Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled
- Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease
- Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
- Amgen Establishes Commercial Operations in Brazil
- Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis
- FDA approves orphan drug vandetanib